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We would like to thank G. Sikri and S. Bhattachar for their
insightful comment [1] on our article suggesting a role of
low-grade cellular-based inﬂammation as indicated by ele-
vated soluble urokinase-type plasminogen activator receptor
(suPAR) plasma concentrationon in the pathogenesis of high
altitude pulmonary edema (HAPE) [2].
The adaptation of the cardiovascular system to hypobaric
hypoxia is an important entity in all high altitude studies.
Recent data from a study using pharmacological blockade
of the sympathetic and parasympathetic nervous system [3]
suggest that even though sympathetic nervous system activity
increases as compared to normoxic state, parasympathetic
withdrawal rather than sympathetic activation seems to be
the cause of the increase in heart rate observed in healthy
humans subjected to hyperbaric hypoxia. Even though the
eﬀect of dexamethasone on the autonomic nervous system
is not fully understood, dexamethasone administration has
previously been shown to decrease heart rate during hypoxic
exposure [4]. It is thus in concordance with current literature
that dexamethasone intake is the likely cause of the diﬀerent
course of HR during hypoxic exposure seen in our study
population (ΔHR +16/min versus −7/min, p < 0 01, in the
no prophylaxis (n = 31) versus the dexamethasone prophylaxis
(n = 10) group).
As G. Sikri and S. Bhattachar point out, it is empirically
known that HAPE incidence at altitude can only be assessed
after several days of high altitude exposure. We agree, epide-
miological studies have clearly shown that HAPE is a hydro-
static type of pulmonary edema which develops within the
ﬁrst days but no later than ﬁve days of exposure to high alti-
tude. In the setting of the Margherita studies, we observed
that up to 70% of the HAPE susceptible mountaineers
develop HAPE within 72 hours of arrival [5, 6]. Results of a
recent study of hemodynamic adaptation to a constant alti-
tude of 3454m over three weeks further suggest the occur-
rence of early pulmonary vascular remodeling within less
than 21 days as an underlying mechanism for a subsequent
decrease in HAPE incidence [7]. Our study was designed
to answer the question whether low-grade cellular-based
inﬂammation as indicated by elevated suPAR plasma con-
centration could predict HAPE susceptibility. Even though
our data indicates such a connection, the question if suPAR
plasma concentration also correlates with HAPE incidence
at altitude remains unanswered. As described in our study,
after the ﬁrst 24 hours at altitude, subjects that have not
received dexamethasone prophylaxis before ascent were
randomized into a group that received post exposure (“late”)
prophylaxis of 8mg oral dexamethasonebidaily (n = 20) and a
Hindawi
Mediators of Inﬂammation
Volume 2018, Article ID 8036759, 2 pages
https://doi.org/10.1155/2018/8036759
control group that did not receive dexamethasone (n = 11).
Thus, HAPE incidence at high altitude depended on dexa-
methasone administration, and the groups are not large
enough for a subgroup analysis regarding baseline suPAR
plasma concentration. It is however of interest that dexa-
methasone application at high altitude partly reversed the
hypoxia-associated increase in suPAR and interleukin-6
(IL-6) plasma concentration within 48 hours, while this was
not the case for c-reactive protein (CRP; see Table 1).
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Table 1: Development of suPAR, CRP, and IL-6 plasma concentration during 48 hours of exposure to 4559m.
High altitude, 24 hours High altitude, 72 hours p value, delta median (95% CI)
suPAR [ng/ml]
Entire sample (n = 31) 2.27 (2.20) 2.08 (2.00) p = 0 34, Δ0.10 (−0.05–0.20)
No steroids (n = 11) 2.13 (2.00) 2.03 (1.90) p = 0 34, Δ-0.15 (−0.35–0.10)
Therapy (n = 20) 2.33 (2.25) 2.11 (2.05) p = 0 04, Δ0.20 (0.00–0.30)
CRP [mg/l]
Entire sample (n = 31) 3.57 (2.20) 3.43 (2.60) p = 0 77, Δ0.10 (−0.75–1.40)
No steroids (n = 11) 1.81 (1.60) 2.76 (2.60) p = 0 08, Δ-1.13 (−2.70–0.05)
Therapy (n = 20) 4.45 (2.50) 3.76 (2.50) p = 0 18, Δ1.25 (−0.30–2.40)
IL-6 [ng/l]
Entire sample (n = 31) 2.71 (2.05) 1.51 (0.73) p = 0 01, Δ1.04 (0.23–2.60)
No steroids (n = 11) 2.45 (2.05) 2.67 (1.75) p = 0 58, Δ0.33 (−3.19–1.25)
Therapy (n = 20) 2.91 (2.21) 0.64 (0.34) p = 0 01, Δ2.18 (0.69–4.06)
Comparison of inﬂammatory marker plasma concentration at 24 versus 72 hours was performed using related sample Wilcoxon signed rank test. Values are
given as median (IQR). Delta median corresponds to the median of the diﬀerence between samples from both timepoints. suPAR: soluble urokinase-type
plasminogen activator receptor; IL-6: interleukin-6; CRP: c-reactive protein; CI: conﬁdence interval.
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